Regarding the HR + HER2- BC population, a phase II study showed the clinical activity of abemaciclib and pharmacokinetic results demonstrated relevant concentrations of abemaciclib and its active metabolites in brain metastases and cerebrospinal fluid. This evidence concerns the gene ERBB2 and breast cancer.